If you are looking for a more effective and innovative antitumor agent for the treatment of multiple sclerosis, it is recommended to buy an innovative remedy, Alemtuzumab( Kampas).In advance it is necessary to familiarize - what for it or him apply, to what group of medicines carry.
This monoclonal antibody prevents the antigen of CD52 lymphocytes. A new prescription drug, which has an immunosuppressive effect, is valued for antitumor effects.
Contents
- General information about the preparation
- Pharmacological action Kampas
- Pharmacokinetic properties
- Ingredients
- Mechanism of action
- Indications and contraindications for use
- For dosages consult a physician!
- Overdosage and additional indications
- Special instructions in the application of
- From the practice of patients and doctors
- Purchase of
preparation General information about the preparation
Why is this new drug needed? For each patient, an experienced neurologist can answer this question in detail. Representing a group of antitumor solutions, Alemtuzumab was created on the basis of a monoclonal antibody.
It was developed in the USA( Cambridge University) back in the late 70s of the last century. The drug is prescribed by doctors to effectively influence leukocytes that are affected by cancer and spoil blood. The drug is recommended for chronic manifestations of multiple sclerosis, appointed in a neurological clinic.
Refers to experimental development containing monoclonal antibodies. It is used in the treatment of multiple sclerosis, characterized by a relapsing-remitting condition of the patient.
This type of MS( multiple sclerosis) is characterized by a wavy flow of periods of exacerbation. Therefore, when choosing the most effective drugs to reduce the inflammatory focus in the central nervous system, do not forget about the innovative developments from this group of drugs.
Pharmacological Effects Kampas
According to statistics and scientific publications, the drug in question can significantly reduce the number of relapses. With therapy, which is based on this remedy, the disease recedes 75% more often when comparing the effects of conventional agents based on interferon beta.
The probability of loss of ability to work with a metered dose of Alemtuzumab is ¾ lower than in traditional methods of treatment.
Patients undergoing treatment with the drug in the system, after 3 years, restore some functions that were previously lost irretrievably.
Patients, according to the results of the research, become more active and healthier from those clients who had to receive traditional therapy( beta interferon).In the latter, progressive disturbances are recorded with subsequent loss of activity.
Information on client status is confirmed by scanning the hemispheres, where it is shown that patients receiving Alemtuzumab doses have an enlarged brain and the remaining patients are characterized by reduced hemispheres.
Researchers state the fact that the systemic use of the drug contributes to the effective recovery of impaired sites in the brain.
Pharmacokinetic properties of
In the international system this compound is referred to as Alemtuzumab. The primary single-dose IV infusion is 75 mg of the active ingredient. The results can only be obtained from the correct dosage of the medication administered intravenously.
The medication concentration is increased every month of therapy. By the middle of the second month( 6 weeks), stable indicators with a higher concentration of the ingredient in the serum are achieved. This helps reduce lymphocytosis, activated on the basis of tumor processes.
Patients suffering from memory disorders, disorders in which more than 30,000 / μL of white blood cells in the blood are characterized by a peak concentration of the drug expressed by leukocytosis.
In the first 1.5 months.treatment, the effect of the drug is significantly lower when compared with patients who have a lymphocyte count of less than 30,000 / μl.
With increased concentration of lymphocytes( malignant), a pool of blood cells is formed, where this composition of the drug accumulates.
A significant decrease in lymphocytosis eliminates the pool, while simultaneously increasing the Cmin and Cmax values of the injected agent in the serum. The spread in the characteristics of pharmacokinetic data is confirmed by the difference in tumor formations.
Ingredients
Solution solutions can be colorless or have a light yellow structure, are issued in pharmacy transparent and 
opalescent substances. In retail, concentrate is presented. The drug is used in the preparation of a solution of infusion 1 ml Alemtuzumab. Use 10 mg of the drug and 30 mg of additional substances.
Ingredients:
- disodium edetate ;
- with phosphate salt buffer with constituents: potassium chloride, potassium dihydrogenphosphate, sodium chloride, sodium phosphate dibasic, polysorbate 80, water( for injection).
Available for sale in ampoules of 3 ml( 10 mg / ml), bottles of 1 ml( 30 mg / ml) with a package of 3 units.
Mechanism of action
Preparation It provokes lymphocyte lysis by directly interacting with CD52( antigen), which is not modulated, is able to be expressed on B and T lymphocytes, including monocytes, thymocytes and macrophages.
In the case of lymphocyte crises, where the indirect effect of the antibody has an indirect effect, complement fixation is noted, an antibody-dependent cytotoxic cellular effect. Specific antigen is found on an insignificant part of granulocyte( up to 5%), does not affect platelets, red blood cells. The medicine spares the stem hematopoietic cells, the precursors.
Indications and contraindications for use
Alemtuzumab is recommended for use in dosage - 1 time / week.(intravenous infusion) for the treatment of multiple sclerosis, with a limiting dosage of 3 mg. The amount is increased in accordance with the prescribed treatment regimen, lasting for no more than 2 months.
Among the direct limitations for the use of the Kampas remedy are:
- for women - the period of the baby's feeding;
- hypersensitivity in anaphylactic reactions, manifestations on the drug taken in the system;
- when allergic to mouse protein, other substances that are present in the drug;
- acute form of drug intolerance;
- exacerbation in the systemic process of an infectious chronic disorder;
- presence of HIV;
- malignant tumors;
- state of pregnancy.
For dosages consult a physician!
The remedy is new and difficult to apply, so you need to know the dosage and the regimen of the therapy from the attending physician who can monitor the patient's condition and correctly prescribe a course of treatment.
It is important to have considerable experience in conducting antitumor therapy, then the dosage and the way of using this ingredient will not be difficult to determine.
Much depends on the form of release, as well as the diagnosis of concomitant diseases, the degree of neglect of the detected relapse.
When treating this medication, the clinic of elderly patients is carefully monitored.
Overdosage and additional indications
Considering the side effects of the drug, experts state that patients who received a repeated dose of up to 240 mg have an overdose. In such situations, fix:
- arterial hypotension;
- signs of fever;
- significant anemia( III-IV grade, NCI count).
Signs of overdose can be characterized by fever, allergic reactions of the body. In such situations, the administration of the drug is canceled, no specific antidote is detected.
Special instructions for the use of
For patients, premedication is carried out with the help of antihistamines. Up to 1 dose, with effective treatment, is prescribed non-narcotic analgesics. With increasing doses, clinical data are analyzed, and special precautions are taken when infusions are taken.
This product is not recommended for pregnancy, lactation. The solution is not combined with other forms. When systemic treatment of multiple sclerosis, the prescribed solutions are not simultaneously found through the common infusion system.
Admission by children is excluded. For drivers of vehicles it is recommended to be cautious - confusion is observed, drowsiness, decreased efficiency, general activity may occur.
Not recommended for use in cases of impaired liver and kidney function. The general term of treatment of MS is from a month, but not more than 3 months.
From the practice of patients and doctors
The drug is new, but there are already reviews about Alemtuzumab in the network.
I had a rash after injections of Alemtuzumab. The allergy was gone by itself, so there is nothing dangerous for health, but was able to quickly recover, became more collected at work.
Sergey, 46, Moscow
I had to treat multiple sclerosis with a new drug - Alemtuzumab( in pharmacies this drug occurs as Alemtuzumab).In the first two phases of the study, the high efficacy of this agent was noted. Experts noted the strong impact on the body of this immunosupressor, an overdose is fraught with side effects. ..
Rosa Vladlenovna, neurologist, Krasnodar
On the forums I got acquainted with the info on this drug. It turns out that the 3rd phase of the planned studies has not yet been completed, and the drug offered in pharmacies has not yet been formally recommended for memory-impaired people.
Vladimir, 51, Penza
I know that Alemtuzumab cures certain types of cancerous tumors. In the drugstores of the country it is not difficult to find, but as a doctor I strictly recommend going through treatment under the strict guidance of practicing neurologists and other specialists of the local clinic.
Nelli Alexandrovna, neurologist, Tyumen
Purchase of
remedy The drug is dispensed as prescribed by the doctor and the prescription is available.
Storage of the product is recommended in the refrigerator at a temperature of 2-8 degrees Celsius - in a cool place, protected from direct rays of light. Shelf life - up to 3 years.
